Can we harmonize classification of TP53 mutant MDS/AML?
In this issue of Blood Advances, Shah et al1 provide an evidence-based proposal to harmonize the classification of TP53 mutant myelodysplastic neoplasms (M
Related Articles
Pushing Forward With Hematology Clinical and Research Efforts in Chaotic, Uncertain Times | ASH Clinical News | American Society of Hematology
Andrew J. Cowan, MD, is an associate professor at the University of Washington and the Clinical Research Division of Fred Hutchinson Cancer Center in Seattle.…
How I treat Wiskott-Aldrich syndrome
Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder with highly variable clinical presentation. In this How I Treat article, Vallée and coauthors pr
A rare phenotype of peripheral T-cell lymphoma, NOS: coexpression of CD15, CD20, and T follicular helper markers in a DUSP22alt case
Muna Al Jabri, Ali Sakhdari; A rare phenotype of peripheral T-cell lymphoma, NOS: coexpression of CD15, CD20, and T follicular helper markers in a DUSP22…
Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022
Key PointsNivolumab plus relatlimab was overall safe, tolerable, and manageable with no unexpected safety signals or treatment-related deaths.The combinati
Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution
Key PointsCAR T cells induce a cellular and humoral immunodeficiency resulting in an initial susceptibility for bacterial and later viral infections.Severe
Iron overload in HFE-related hemochromatosis severely impairs Vδ2+ γδ T-cell homeostasis
Key PointsIron overload in HFE-related hemochromatosis and thalassemia leads to reversal of the Vδ2+/Vδ2– ratio in the γδ T-cell compartment.Iron promotes
Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens
Key Points. BCMA antigen expression is controlled by the ubiquitin-proteasome system in a p97-dependent manner at the plasma membraneElevation of BCMA cell
Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury
Key PointsEarly use of daratumumab combinations in patients with MM admitted with kidney injury rapidly reduces sFLCs.Early initiation of daratumumab combi
Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement
Key PointsCREBBP mutations create a zombie enzyme that inhibits EP300 and blunts CD40-responsive chromatin loading and enhancer activation.Enforcing CD40 s